Product Description
BAY-2701439 is being developed by Bayer for the treatment of patients with Advanced Cancer Expressing the HER2 Protein. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04147819?term=BAY-2701439&draw=2&rank=1)
Mechanisms of Action: HER2 Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Bayer
Company Location:
Company Founding Year: 1863
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Esophageal Cancer|Breast Cancer|Gastrointestinal Cancer|Liver Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04147819 |
NCT04147819 | P1 |
Completed |
Esophageal Cancer|Gastrointestinal Cancer|Breast Cancer|Liver Cancer |
2023-08-21 |
2023-10-19 |
Recent News Events
Date |
Type |
Title |
|---|